Shenzhen Rhegen Biotechnology Co., Ltd.
https://www.rhegen.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Shenzhen Rhegen Biotechnology Co., Ltd.
Recbio First Biotech To Brave A Hong Kong IPO In 2022
Chinese vaccine maker Recbio hopes an IPO in Hong Kong will bring investor attention to its mRNA COVID vaccine with potential against the Omicron variant.
China’s Lead mRNA COVID-19 Vaccine Candidate Faces Phase III Delays
The leader in China's homegrown mRNA COVID-19 vaccine effort expects a delay to key Phase III results, with analysts now expecting to see figures from the international portion of the study in early 2022.
Company Information
- Industry
- Biotechnology
- Contract Research Organization-CRO
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Shenzhen Rhegen Biotechnology Co., Ltd.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice